IMS Conducts Study for U.S. Drug Enforcement Administration to Help Combat National Methamphetamine Epidemic.Quotas Established for Legitimate Medical Use of Ephedrine ephedrine (ĭfĕd`rĭn, ĕf`ĭdrēn'), drug derived from plants of the genus Ephedra (see Pinophyta), most commonly used to prevent mild or moderate attacks of bronchial asthma. and Pseudoephedrine pseudoephedrine /pseu·do·ephed·rine/ (-e-fed´rin) one of the optical isomers of ephedrine; used as the hydrochloride or sulfate salt as a nasal decongestant. pseu·do·e·phed·rine n. FAIRFIELD, Conn. -- IMS Health (NYSE NYSE See: New York Stock Exchange : RX), the world's leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced it has completed a study for the U.S. Drug Enforcement Administration The Drug Enforcement Administration (DEA) was established in 1973 by President richard m. nixon as part of the Justice Department, thus uniting a number of federal drug agencies that had often worked at cross-purposes. (DEA DEA - Data Encryption Algorithm ) to help determine the quantity of ephedrine and pseudoephedrine necessary for legitimate medical usage in the United States. The U.S. Combat Methamphetamine Epidemic Act of 2005 required the DEA to establish production and importation quotas for chemicals that can be diverted for the clandestine manufacture of methamphetamine, one of the nation's most powerful and heavily abused drugs. IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. assisted the DEA by conducting a thorough analysis of sales and utilization patterns for these chemicals by cross referencing five separate IMS prescription drug information sources with over-the-counter sales data. The study concluded that 3,800 kg of ephedrine and 350,700 kg of pseudoephedrine were required to meet the nation's current legitimate patient medical needs for these products. "This study for the DEA underscores the critical role that robust pharmaceutical information plays in driving appropriate drug utilization and protecting patient safety," said Mark Tanen, Vice President, IMS Government Solutions. "We remain committed to applying our market intelligence to the needs of a broad range of stakeholders to serve the public's interests and improve the quality of healthcare." The IMS Report was summarized in a recent edition of the Federal Register (Vol. 71, No. 202). The full report is available on the DEA Diversion Web site at www.deadiversion.usdoj.gov. About IMS Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With $1.8 billion in 2005 revenue and more than 50 years of industry experience, IMS offers leading-edge business intelligence products and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and over-the-counter offerings; and consulting and services solutions that improve ROI (Return On Investment) The monetary benefits derived from having spent money on developing or revising a system. In the IT world, there are more ways to compute ROI than Carter has liver pills (and for those of you who never heard of that expression, it means a lot). and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion